Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.
The post ESCMID Global 2026: TherVacB Phase I data supports continued development appeared first on Clinical Trials Arena.
New York City-based NYU Langone Health recorded an operating income of $107.1 million (2.6% operating margin) in the second quarter of 2026, up from an operating …
[Sponsored] Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to …
Ever get so mad you could just… run a mile? Anger can be fiery fuel for a serious sweat session — and that exercise, in turn, …
التوازن الغذائي لا يحدد فقط قدرة الجسم على مقاومة الأمراض، بل يؤثر أيضًا على احتمالات حدوث التهابات مزمنة أو اضطرابات مناعية.